InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,908.51
(
-0.68%
)
US TECH 100
20,141.60
(
-1.01%
)
Dow Jones
43,617.67
(
-0.30%
)
Brent Oil
71.73
(
-0.67%
)
Bitcoin
89,191.95
(
2.11%
)
Post# of 253612
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 85722

Monday, 03/01/2010 1:58:41 PM

Monday, March 01, 2010 1:58:41 PM

Post# of 253612
End of the way for narlaprevir (SCH 900518), MK-7009 is the chosen one:

Merck had to choose among similar drugs in two research areas: hepatitis C and cancer. In December, Merck said its hepatitis C drug, MK-7009, also known as vaniprevir, would take priority over a similar drug from Schering.


http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201003011141dowjonesdjonline000505&title=merck-touts-heart-infection-drugs-in-pipeline-update
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up